Endocrine Abstracts

Background: Cardiometabolic polycystic ovary syndrome (PCOS) phenotype is predominantly characterized by obesity. It is clearly associated with impaired metabolic and reproductive health, whereas implications on cardiac health are mostly limited with the exploration of cardiovascular risk factors without actual cardiovascular endpoints. There is a relative lack of systematic prospective studies investigating long-term effects of different treatment options that include phenoty...

Introduction: Somapacitan is 23.3-kDa human GH derivate linked to small noncovalent albumin binding moiety that facilitates reversible endogenous albumin binding to delay somapacitan elimination. The longer half-life and improved pharmacodynamics allow injections once per week. Some patients find a daily regimen with established treatment difficult, especially because treatment may be lifelong or at least for several years. Poor adherence with medication can lead to poorer cli...

Objective: Metformin is the first-line therapy for PCOS with high metabolic risk, yet a large proportion of patients cannot tolerate it due to associated gastrointestinal adverse events. The alternative pharmacological strategy when metformin cannot be tolerated is not well established in this population. Our aim was to evaluate whether sitagliptin (SITA) preserves metabolic profile in metformin (MET) intolerant PCOS with high metabolic risk.Design and m...

Introduction: High conversion rates to impaired glucose tolerance (IGT) and diabetes in PCOS indicate that current treatment strategy with lifestyle modification and metformin is insufficient. Preservation of β-cell function remains unaddressed although it is declined by 80% long before IGT is identified. Alogliptin is selective dipeptidyl peptidase-4 inhibitor improving insulin sensitivity (IS) and β-cell function. Pioglitazone predominantly improv...

Objective: Bone strength post heart transplant (HT) is affected by many factors including glucocorticoids, calcineurin inhibitors, hypogonadism, vitamin D deficiency, secondary hyperparathyroidism and cachexia. Trabecular bone score (TBS), novel texture index derived from lumbar spinal DXA improves fracture risk assessment in several different high-risk populations, whereas it remains largely understudied in HT recipients. We aimed to evaluate factors that affect TBS after HT....

Objective: Studies comparing endocrine and metabolic outcomes of childhood- and adult-onset craniopharyngioma (CP) are generally based on the age-of-disease onset only. The aim of this study was to analyze the role of histological tumor subtype (adamantinomatous (aCP) or papillary (pCP)) on the development of long-term endocrine and metabolic CP comorbidities.Methods: 47 patients with CP treated from 1979 onwards (19 patients with childhood-onset disease...

Objective: Impaired glucose homeostasis in PCOS is closely linked to obesity, age and disease phenotype. The potential separate role of reduced GLP-1 response in the development of prediabetes in this population is unclear.Aim: To compare the GLP-1 response after OGTT in a cohort of obese PCOS with normal glucose tolerance (NGT) and prediabetes.Design/participants/methods: Case control study recruited 26 obese Caucasian women with ...

Introduction: Double aneuploidies are extremely rare. Klinefelter syndrome is a chromosomal disorder characterized by an extra X chromosome in male cells - approximately 80% are 47,XXY; the remaining 20% are mosaic 47,XXY/46,XY. Down syndrome is caused by trisomy of chromosome 21. The prevalence of Klinefelter syndrome is approximately 1 to 2.5 per 1000 boys and men (0.1 to 0.25 percent). The incidence of Down syndrome is approximately 1 in every 990 live births across Europe ...

Objective: We aimed to evaluate the ability of SAGIT Instrument and AcroQoL questionnaire to discriminate acromegaly control status and to correlate SAGIT scores to AcroQoL results in a cohort of the national referral centre.Methods: Cross-sectional study included 72 patients followed between 2000 and 2020. We retrospectively determined SAGIT score at the diagnosis. Based on the data from the most recent follow up and additional telephone interviews, we ...

Background: Withdrawal of anti-obesity medication is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. In STEP 1 trial extension participants regained two-thirds of their prior weight loss during the 1-year off-treatment follow-up period after withdrawal of semaglutide 2.4 mg and discontinuation of active lifestyle intervention support. There are some studies implying that metformin might attenuat...